B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Proceedings ArticleDOI
Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients
David F. McDermott,Mahrukh Huseni,Brian I. Rini,Robert J. Motzer,Michael B. Atkins,Berard Escudier,Dorothee Nickles,Zach Boyd,Shruthi Sampath,Jennifer Doss,Ning Leng,Christina Schiff,Daniel S. Chen,Gregg Fine,Thomas Powles,Priti S. Hegde +15 more
TL;DR: In this paper, a phase II trial that compared atezo+/-bev vs sunitinib (sun) in untreated metastatic renal cell carcinoma (RCC) patients, encouraging antitumor activity of bevacizumab (bev) vs sun was observed in PD-L1 expressing tumors.
Journal ArticleDOI
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
Robert Dreicer,Jorge A. Garcia,Maha Hussain,Brian I. Rini,Nicholas J. Vogelzang,Sandy Srinivas,Bradley Somer,Yan D. Zhao,Marek Kania,Derek Raghavan +9 more
TL;DR: Enzastaurin as a single agent has limited activity in castrate progressive prostate cancer, and evaluation in combination with docetaxel is ongoing.
Journal ArticleDOI
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)
Hyung L. Kim,Susan Halabi,Ping Li,Greg Mayhew,Jeff Simko,Andrew B. Nixon,Eric J. Small,Brian I. Rini,Michael J. Morris,Mary-Ellen Taplin,Daniel J. George +10 more
TL;DR: A molecular prognostic signature based on 8 genes was developed and is ready for external validation in this patient population and other related settings such as nonmetastatic RCC.
Journal ArticleDOI
Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).
Eric Jonasch,Elshad Hasanov,Robert J. Motzer,Subramanian Hariharan,Toni K. Choueiri,Bo Huang,John B. A. G. Haanen,Laurence Albiges,Balaji Venugopal,Manuela Schmidinger,James Larkin,Marc-Oliver Grimm,Sylvie Negrier,Jing Wang,Mariangela Mariani,Aleksander Chudnovsky,Alessandra di Pietro,Brian I. Rini +17 more
TL;DR: The phase 3 JAVELIN Renal 101 trial shows good results in patients with brain metastasis from renal cell carcinoma with poor prognosis, and the data indicates that further studies are needed to assess the applicability of this data to clinical practice.
Journal ArticleDOI
Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC)
Frede Donskov,M.D. Michaelson,Igor Puzanov,Mellar P. Davis,G. A. Bjarnason,Robert J. Motzer,Xun Lin,Darrel P. Cohen,Robin Wiltshire,Brian I. Rini +9 more
TL;DR: Combined multivariate analyses indicate that HTN and HFS, and to a lesser degree A/F, may serve as independent biomarkers of sunitinib efficacy in mRCC patients and are encouraged to continue sunit inib therapy, managing AEs with standard medical treatment with or without dose reduction as clinically indicated.